drugset / Trial / NCT07110558

Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma

NCT07110558 ↗

Phase 2 Not yet recruiting 59 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This single-arm, phase 2 trial evaluates the efficacy and safety of de-escalated radiotherapy (restricted to the primary tumor, omitting prophylactic neck irradiation) combined with neoadjuvant and adjuvant toripalimab immunotherapy, and concurrent chemotherapy in patients with nasopharyngeal carcinoma staged N0 or N1, where nodal involvement is strictly confined to the retropharyngeal lymph nodes.

Timeline

Start
2025-08-15
Primary completion
2029-08-14
Completion
2032-08-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Background Cisplatin Other / unclassified 100 mg/m2 Intravenous